PMID- 22500694
OWN - NLM
STAT- MEDLINE
DCOM- 20120925
LR  - 20221207
IS  - 1746-1596 (Electronic)
IS  - 1746-1596 (Linking)
VI  - 7
DP  - 2012 Apr 13
TI  - Genomic amplification patterns of human telomerase RNA gene and C-MYC in 
      liquid-based cytological specimens used for the detection of high-grade cervical 
      intraepithelial neoplasia.
PG  - 40
LID - 10.1186/1746-1596-7-40 [doi]
AB  - BACKGROUND: The amplification of oncogenes initiated by high-risk human 
      papillomavirus (HPV) infection is an early event in cervical carcinogenesis and 
      can be used for cervical lesion diagnosis. We measured the genomic amplification 
      rates and the patterns of human telomerase RNA gene (TERC) and C-MYC in the 
      liquid-based cytological specimens to evaluate the diagnostic characteristics for 
      the detection of high-grade cervical lesions. METHODS: Two hundred and 
      forty-three residual cytological specimens were obtained from outpatients aged 25 
      to 64 years at Qilu Hospital, Shandong University. The specimens were evaluated 
      by fluorescence in situ hybridization (FISH) using chromosome probes to TERC 
      (3q26) and C-MYC (8q24). All of the patients underwent colposcopic examination 
      and histological evaluation. A Chi-square test was used for categorical data 
      analysis. RESULTS: In the normal, cervical intraepithelial neoplasia grade 1 
      (CIN1), grade 2 (CIN2), grade 3 (CIN3) and squamous cervical cancer (SCC) cases, 
      the TERC positive rates were 9.2%, 17.2%, 76.2%, 100.0% and 100.0%, respectively; 
      the C-MYC positive rates were 20.7%, 31.0%, 71.4%, 81.8% and 100.0%, 
      respectively. The TERC and C-MYC positive rates were higher in the CIN2+ (CIN2, 
      CIN3 and SCC) cases than in the normal and CIN1 cases (p < 0.01). Compared with 
      cytological analysis, the TERC test showed higher sensitivity (90.0% vs. 84.0%) 
      and higher specificity (89.6% vs. 64.3%). The C-MYC test showed lower sensitivity 
      (80.0% vs. 84.0%) and higher specificity (77.7% vs. 64.3%). Using a cut-off value 
      of 5% or more aberrant cells, the TERC test showed the highest combination of 
      sensitivity and specificity. The CIN2+ group showed more high-level TERC gene 
      copy number (GCN) cells than did the normal/CIN1 group (p < 0.05). For C-MYC, no 
      significant difference between the two histological categories was detected (p > 
      0.05). CONCLUSIONS: The TERC test is highly sensitive and is therefore suitable 
      for cervical cancer screening. The C-MYC test is not suitable for cancer 
      screening because of its lower sensitivity. The amplification patterns of TERC 
      become more diverse and complex as the severity of cervical diseases increases, 
      whereas for C-MYC, the amplification patterns are similar between the normal/CIN1 
      and CIN2+ groups. VIRTUAL SLIDES: The virtual slide(s) for this article can be 
      found here: http://www.diagnosticpathology.diagnomx.eu/vs/1308004512669913.
FAU - Chen, Shaomin
AU  - Chen S
AD  - Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, 
      Jinan, Shandong 250012, People's Republic of China.
FAU - Yang, Ziyan
AU  - Yang Z
FAU - Zhang, Yun
AU  - Zhang Y
FAU - Qiao, Yunbo
AU  - Qiao Y
FAU - Cui, Baoxia
AU  - Cui B
FAU - Zhang, Youzhong
AU  - Zhang Y
FAU - Kong, Beihua
AU  - Kong B
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120413
PL  - England
TA  - Diagn Pathol
JT  - Diagnostic pathology
JID - 101251558
RN  - 0 (DNA, Neoplasm)
RN  - 0 (telomerase RNA)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - Adult
MH  - Cytological Techniques
MH  - DNA, Neoplasm/genetics
MH  - Female
MH  - *Gene Amplification
MH  - Genes, myc/*genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Prognosis
MH  - RNA/*genetics
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
MH  - Telomerase/*genetics
MH  - Uterine Cervical Neoplasms/*diagnosis/genetics/pathology
MH  - Uterine Cervical Dysplasia/*diagnosis/genetics/pathology
PMC - PMC3379933
EDAT- 2012/04/17 06:00
MHDA- 2012/09/26 06:00
PMCR- 2012/04/13
CRDT- 2012/04/17 06:00
PHST- 2012/01/31 00:00 [received]
PHST- 2012/04/13 00:00 [accepted]
PHST- 2012/04/17 06:00 [entrez]
PHST- 2012/04/17 06:00 [pubmed]
PHST- 2012/09/26 06:00 [medline]
PHST- 2012/04/13 00:00 [pmc-release]
AID - 1746-1596-7-40 [pii]
AID - 10.1186/1746-1596-7-40 [doi]
PST - epublish
SO  - Diagn Pathol. 2012 Apr 13;7:40. doi: 10.1186/1746-1596-7-40.